ClinicalTrials.gg
CompletedNCT03537014Updated Jun 6, 2025Results posted

A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)

A Phase 3 interventional study of Therapy and midomafetamine HCl in Posttraumatic Stress Disorder, sponsored by Lykos Therapeutics. Completed at 15 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-06.

Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic — 11 open to participants now, 12 under way, 1 of them phase 3. N-Methyl-3,4-methylenedioxyamphetamine · Stress Disorders, Post-Traumatic.

Enrollment
5th of 38
100 · median 25
Started
2018
with 2 others
Phase 3
6 of 38
none open now
Registered
12th of 38
by date
Lead sponsor
16 of 38
Lykos Therapeutics

Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, this one is the 5th largest by enrollment, is one of 3 that started in 2018, is one of 6 in phase 3, and was the 12th registered.

Stress Disorders, Post-Traumatic

2,688 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 606 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

11 of the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic are open now, in 3 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About N-Methyl-3,4-methylenedioxyamphetamine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with at least severe PTSD.

The main question it aims to answer is: Do three sessions of MDMA-assisted therapy reduce PTSD symptoms?

Researchers will compare three sessions of MDMA-assisted therapy with an initial dose of 80 to 120 mg to three sessions of placebo with therapy.

Participants will undergo three preparatory sessions without any study drug, followed by three MDMA-assisted therapy or placebo with therapy sessions. Each medication session will be followed by three integrative therapy sessions without study drug.

Read the detailed description

This multi-site, double-blind, placebo-controlled, randomized Phase 3 study will assess the efficacy and safety of MDMA-assisted therapy versus placebo with therapy in participants diagnosed with at least severe PTSD. The study will be conducted in N ≈ 100 participants. Participants will be randomized to one of two groups at a 1:1 ratio. An initial dose of midomafetamine HCl or placebo, followed by a supplemental half-dose unless contraindicated, is administered during the Treatment Period with manualized therapy in three monthly Experimental Sessions. This \~12-week Treatment Period is preceded by three Preparatory Sessions. During the Treatment Period, each Experimental Session is followed by three Integrative Sessions of non-drug psychotherapy. Initial doses per Experimental Session include 80 mg or 120 mg of midomafetamine HCl or placebo followed 1.5 to 2 hours later by a supplemental half-dose (40 or 60 mg). Total amounts of midomafetamine HCl to be administered per Experimental Session range from 80 mg to 180 mg.

The primary endpoint is change from baseline in Clinician Administered PTSD Scale for DSM-V (CAPS-5) to 18 weeks post-Baseline. Drug safety will be assessed by measuring blood pressure, heart rate and body temperature during Experimental Sessions, collecting adverse events and measuring suicidal thoughts or behaviors with the Columbia Suicide Severity Rating Scale (adapted C-SSRS).

03

Conditions studied

  • Posttraumatic Stress Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are at least 18 years old
  • Are fluent in speaking and reading the predominantly used or recognized language of the study site
  • Are able to swallow pills
  • Agree to have study visits recorded, including Experimental Sessions, Independent Rater assessments, and non-drug psychotherapy sessions
  • Must provide a contact (relative, spouse, close friend or other caregiver) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal or unreachable.
  • Must agree to inform the investigators within 48 hours of any medical conditions and procedures
  • If of , must have a negative pregnancy test at study entry and prior to each Experimental Session, and must agree to use adequate through 10 days after the last Experimental Session.
  • Must not participate in any other interventional clinical trials during the duration of the study
  • Must be willing to remain overnight at the study site after each Experimental Session and be driven home after, and commit to medication dosing, therapy, and study procedures
  • At baseline, meet criteria for current severe PTSD

Exclusion criteria

Exclusion Criteria:

  • Are not able to give adequate
  • Have uncontrolled hypertension
  • Have a marked baseline prolongation of /QTc interval (e.g., repeated demonstration of a QTc interval >450 milliseconds [ms] in males and >460 ms in females corrected by Bazett's formula)
  • Have a history of additional risk factors for Torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
  • Have evidence or history of significant medical disorders, such as myocardial infarction, cerebrovascular accident, or aneurysm
  • Have symptomatic liver disease
  • Have history of hyponatremia or hyperthermia
  • Weigh less than 48 kilograms (kg)
  • Are pregnant or nursing, or are of and are not practicing an effective means of
  • Have an active illicit or prescription drug use disorder
  • Have used Ecstasy (material represented as containing MDMA) more than 10 times within the last 10 years or at least once within 6 months of the first Experimental Session; or have previously participated in a MAPS-sponsored MDMA clinical trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    MDMA-assisted therapy

    Administration of 80 or 120 mg midomafetamine HCl with a supplemental dose 1.5 to 2 hours later of 40 or 60 mg midomafetamine HCl, respectively, in combination with therapy during 3 experimental sessions scheduled 3-5 weeks apart.

    Behavioral: Therapy · Drug: midomafetamine HCl

  • Placebo comparator
    Placebo with therapy

    Administration of inactive placebo in combination with therapy during 3 experimental sessions scheduled 3-5 weeks apart

    Behavioral: Therapy · Drug: Placebo

Interventions

  • BehavioralTherapy

    Non-directive therapy performed by therapist team

    Also known as: Manualized therapy

  • Administration of 80 to 120 mg midomafetamine HCl, followed by a supplemental dose 1.5 to 2 hrs later of 40 or 60 mg midomafetamine HCl, respectively, during three experimental sessions

    Also known as: 3,4-methylenedioxymethamphetamine, MDMA, midomafetamine, MDMA HCl

  • DrugPlacebo

    Administration of placebo during three experimental sessions

    Also known as: Inactive placebo

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Primary Endpoint in Clinician Administered PTSD Scale for DSM-V (CAPS-5)

    The CAPS-5 is a 30-item semi-structured interview assessing PTSD in the past month through diagnostic and symptom severity scores anchored to a DSM-5 defined traumatic event. The CAPS-5 produces a Total Severity Score based on severity of PTSD domains described in the DSM-5, as well as a categorical rating indicating whether a participant meets PTSD diagnostic criteria. CAPS-5 Total Symptom Severity scores range from 0 to 80 with higher values indicating greater symptom severity. CAPS-5 assigns PTSD diagnosis as being present or absent.

    Time frame: Baseline to 18 weeks post enrollment confirmation

Secondary outcomes

  1. Change From Baseline to Primary Endpoint in Sheehan Disability Scale (SDS) Total Score

    The Sheehan Disability Scale (SDS) is a clinician-rated assessment of functional impairment that was adapted for the purposes of this study to limit missing item-level data as per the FDA requirements and included use of the three-item mean as the total score and imputation of work-related impairment. The SDS is a 3-item scale measuring the severity of disability in the domains of work, family life/home responsibilities and social/leisure activities, with each item scored on a ten-point Likert scale from 0 ('not at all impaired') to 10 ('very severely impaired'). The SDS total score was the mean of the 3 item responses. The SDS total score ranged from 0 to 10, with higher scores indicating greater functional impairment.

    Time frame: Baseline to 18 weeks post enrollment confirmation

07

Results

Posted Sep 16, 2021

Participant flow

Participant flow — Overall Study
MilestoneMDMA-assisted TherapyPlacebo With Therapy
Started4645
Completed4237
Not completed48

Outcome measures

PrimaryChange From Baseline to Primary Endpoint in Clinician Administered PTSD Scale for DSM-V (CAPS-5)

The CAPS-5 is a 30-item semi-structured interview assessing PTSD in the past month through diagnostic and symptom severity scores anchored to a DSM-5 defined traumatic event. The CAPS-5 produces a Total Severity Score based on severity of PTSD domains described in the DSM-5, as well as a categorical rating indicating whether a participant meets PTSD diagnostic criteria. CAPS-5 Total Symptom Severity scores range from 0 to 80 with higher values indicating greater symptom severity. CAPS-5 assigns PTSD diagnosis as being present or absent.

Time frame:
Baseline to 18 weeks post enrollment confirmation
Reported as:
Least squares mean · score on a scale
Change From Baseline to Primary Endpoint in Clinician Administered PTSD Scale for DSM-V (CAPS-5)
score on a scaleMDMA-assisted TherapyPlacebo With Therapy
Change From Baseline to Primary Endpoint in Clinician Administered PTSD Scale for DSM-V (CAPS-5)-24.5 (-28.28 to -20.71)-12.64 (-16.61 to -8.66)
SecondaryChange From Baseline to Primary Endpoint in Sheehan Disability Scale (SDS) Total Score

The Sheehan Disability Scale (SDS) is a clinician-rated assessment of functional impairment that was adapted for the purposes of this study to limit missing item-level data as per the FDA requirements and included use of the three-item mean as the total score and imputation of work-related impairment. The SDS is a 3-item scale measuring the severity of disability in the domains of work, family life/home responsibilities and social/leisure activities, with each item scored on a ten-point Likert scale from 0 ('not at all impaired') to 10 ('very severely impaired'). The SDS total score was the mean of the 3 item responses. The SDS total score ranged from 0 to 10, with higher scores indicating greater functional impairment.

Time frame:
Baseline to 18 weeks post enrollment confirmation
Reported as:
Least squares mean · score on a scale
Change From Baseline to Primary Endpoint in Sheehan Disability Scale (SDS) Total Score
score on a scaleMDMA-assisted TherapyPlacebo With Therapy
Change From Baseline to Primary Endpoint in Sheehan Disability Scale (SDS) Total Score-3.15 (-3.90 to -2.40)-1.79 (-2.58 to -1.00)

Adverse events

Collected over During the Treatment Period from the first Experimental Session to the Termination visit (approximately 18 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MDMA-assisted Therapy0/46 (0%)0/46 (0%)46/46 (100%)
Placebo With Therapy0/44 (0%)2/44 (4.5%)44/44 (100%)
Most frequent serious events
Most frequent serious events
EventMDMA-assisted TherapyPlacebo With Therapy
Suicide AttemptPsychiatric disorders0/461/44
Suicidal IdeationPsychiatric disorders0/461/44
Most frequent other events
Showing 10 of 64
Most frequent other events
EventMDMA-assisted TherapyPlacebo With Therapy
HeadacheNervous system disorders33/4624/44
Muscle TightnessMusculoskeletal and connective tissue disorders28/466/44
Decreased AppetiteMetabolism and nutrition disorders24/465/44
Suicidal IdeationPsychiatric disorders21/4621/44
InsomniaPsychiatric disorders20/4613/44
AnxietyPsychiatric disorders15/4617/44
FatigueGeneral disorders14/4614/44
NauseaGastrointestinal disorders14/465/44
HyperhidrosisSkin and subcutaneous tissue disorders10/461/44
Feeling ColdGeneral disorders9/463/44

Baseline characteristics

Safety set

Age, Continuous
Age, Continuous(years)MDMA-assisted TherapyPlacebo With TherapyTotal
Mean43.55 ± 12.8638.19 ± 10.3640.93 ± 11.95
Sex: Female, Male
Sex: Female, Male(Participants)MDMA-assisted TherapyPlacebo With TherapyTotal
Female273259
Male191231
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MDMA-assisted TherapyPlacebo With TherapyTotal
Hispanic or Latino538
Not Hispanic or Latino414081
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MDMA-assisted TherapyPlacebo With TherapyTotal
American Indian or Alaska Native303
Asian257
Native Hawaiian or Other Pacific Islander000
Black or African American022
White393069
More than one race268
Unknown or Not Reported011
Body mass index
Body mass index(kg/m^2)MDMA-assisted TherapyPlacebo With TherapyTotal
Mean26.0 ± 4.824.8 ± 4.225.4 ± 4.5
Duration of PTSD
Duration of PTSD(years)MDMA-assisted TherapyPlacebo With TherapyTotal
Mean14.8 ± 11.613.3 ± 11.414.0 ± 11.5
Dissociative subtype of PTSD
Dissociative subtype of PTSD(Participants)MDMA-assisted TherapyPlacebo With TherapyTotal
Count of participants61319
08

Study locations

15 sites
  • New School Research LLT
    North Hollywood, California 91601, United States
  • San Francisco Insight and Integration Center
    San Francisco, California 94114, United States
  • University of California San Francisco
    San Francisco, California 94122, United States
  • Aguazul-Blue Water Inc.
    Boulder, Colorado 80302, United States
  • Wholeness Center
    Fort Collins, Colorado 80525, United States
  • Ray Worthy Psychiatry LLC
    New Orleans, Louisiana 70123, United States
  • Trauma Research Foundation
    Boston, Massachusetts 02446, United States
  • New York University
    New York, New York 10016, United States
  • New York Private Practice
    New York, New York 10024, United States
  • Zen Therapeutic Solutions, LLC
    Mount Pleasant, South Carolina 29464, United States
  • University of Wisconsin at Madison
    Madison, Wisconsin 53705, United States
  • Providence Health Center
    Vancouver, British Columbia V5R 5H3, Canada
  • Dr. Simon Amar, Inc.
    Montreal, Quebec H2W1Y9, Canada
  • Assaf Harofeh Research Fund
    Be'er Ya'akov, Israel
  • Sheba Fund for Health Services and Research
    Tel HaShomer, Israel
09

References and documents

Publications

  • Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, Ot'alora G M, Garas W, Paleos C, Gorman I, Nicholas C, Mithoefer M, Carlin S, Poulter B, Mithoefer A, Quevedo S, Wells G, Klaire SS, van der Kolk B, Tzarfaty K, Amiaz R, Worthy R, Shannon S, Woolley JD, Marta C, Gelfand Y, Hapke E, Amar S, Wallach Y, Brown R, Hamilton S, Wang JB, Coker A, Matthews R, de Boer A, Yazar-Klosinski B, Emerson A, Doblin R. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021 Jun;27(6):1025-1033. doi: 10.1038/s41591-021-01336-3. Epub 2021 May 10. PubMed 33972795 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — We will share outcome data appearing in any published reports upon request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data and study-related documents will be available when the database has been locked and data has been unblinded.

Access criteria: Interested persons should correspond with the central contact for the multisite study.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Aug 2020, 20 months.

Results were first posted in Sep 2021, 1 year 1 month after primary completion.

Of 34 phase 3 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2018
First posted
May 25, 2018
StartActual
Nov 21, 2018
Primary completionActual
Aug 11, 2020
CompletionActual
Aug 21, 2020
Results first posted
Sep 16, 2021
Last update
Jun 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03537014
Lead sponsor
Lykos Therapeutics
Responsible party
Sponsor
First posted
May 25, 2018
Start date
Nov 21, 2018
Primary completion
Aug 11, 2020
Completion
Aug 21, 2020
Results posted
Sep 16, 2021
Last update
Jun 6, 2025

Study contacts

Casey Paleos, MD
principal investigator · Affective Care
Bessel van der Kolk, MD
principal investigator · Trauma Research Foundation
Emma Hapke, MD
principal investigator · Dr. Simon Amar, Inc.
Revital Amiaz, MD
principal investigator · The Chaim Sheba Medical Center, Tel Hashomer Hospital
Michael Bogenschutz, MD
principal investigator · New York University/Langone Medical Center/Bellevue Hospital
Randall Brown, MD, PhD
principal investigator · University of Wisconsin, Madison
Sylvestre Quevedo, MD
principal investigator · San Francisco Insight and Integration Center
Josh Woolley, MD, PhD
principal investigator · University of California, San Francisco
Ray Worthy, MD
principal investigator · Ray Worthy Psychiatry, LLC
Cole Marta, MD
principal investigator · New School Research, LLC
Scott Shannon, MD
principal investigator · Wholeness Center
Wael Garas, MD
principal investigator · Aguazul-Bluewater, Inc.
Yevgeniy Gelfand, MD
principal investigator · Zen Therapeutics Solutions, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine

Start the discussion